Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.
Update 31-12-2021: Please note that the study is now active and enrolment is completed.
Study Duration
- 32-36 weeks, including:
- 4-week screening
- 24-week study treatment period
- 4 to 8-week follow-up period
Investigational Drug
- Tofersen (BIIB067), an antisense oligonucleotide (ASO)
- Designed to reduce the amount of SOD1 protein in the body
- Given intrathecally, through a lumbar puncture
Key Eligibility Criteria
- 18 years of age or older
- Have weakness caused by ALS
- Agree to genetic testing for the SOD1 mutation
All Eligible Participants Will Receive At No Cost
- Comprehensive study-related health evaluations and assessments, including genetic testing
- Investigational drug or placebo
- All study-related visits and care
Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view our study locations.
Related news
European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen. […]
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label […]
Meet the centre - Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe. […]
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]